Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Soluble CD4 broadens neutralization of V3-directed monoclonal antibodies and guinea pig vaccine sera against HIV-1 subtype B and C reference viruses.

Wu X, Sambor A, Nason MC, Yang ZY, Wu L, Zolla-Pazner S, Nabel GJ, Mascola JR.

Virology. 2008 Oct 25;380(2):285-95. doi: 10.1016/j.virol.2008.07.007. Epub 2008 Sep 18.

4.
5.

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies.

Binley JM, Wrin T, Korber B, Zwick MB, Wang M, Chappey C, Stiegler G, Kunert R, Zolla-Pazner S, Katinger H, Petropoulos CJ, Burton DR.

J Virol. 2004 Dec;78(23):13232-52.

6.

Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma.

Davis KL, Bibollet-Ruche F, Li H, Decker JM, Kutsch O, Morris L, Salomon A, Pinter A, Hoxie JA, Hahn BH, Kwong PD, Shaw GM.

J Virol. 2009 Feb;83(3):1240-59. doi: 10.1128/JVI.01743-08. Epub 2008 Nov 19.

7.

Production and characterization of human anti-V3 monoclonal antibodies from the cells of HIV-1 infected Indian donors.

Andrabi R, Kumar R, Bala M, Nair A, Biswas A, Wig N, Kumar P, Pal R, Sinha S, Luthra K.

Virol J. 2012 Sep 12;9:196. doi: 10.1186/1743-422X-9-196.

8.

Distinct mechanisms regulate exposure of neutralizing epitopes in the V2 and V3 loops of HIV-1 envelope.

Upadhyay C, Mayr LM, Zhang J, Kumar R, Gorny MK, Nádas A, Zolla-Pazner S, Hioe CE.

J Virol. 2014 Nov;88(21):12853-65. doi: 10.1128/JVI.02125-14. Epub 2014 Aug 27.

10.
11.

Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1.

Gorny MK, Williams C, Volsky B, Revesz K, Wang XH, Burda S, Kimura T, Konings FA, Nádas A, Anyangwe CA, Nyambi P, Krachmarov C, Pinter A, Zolla-Pazner S.

J Virol. 2006 Jul;80(14):6865-72.

13.

The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope.

Gorny MK, Revesz K, Williams C, Volsky B, Louder MK, Anyangwe CA, Krachmarov C, Kayman SC, Pinter A, Nadas A, Nyambi PN, Mascola JR, Zolla-Pazner S.

J Virol. 2004 Mar;78(5):2394-404.

15.

sCD4-17b bifunctional protein: extremely broad and potent neutralization of HIV-1 Env pseudotyped viruses from genetically diverse primary isolates.

Lagenaur LA, Villarroel VA, Bundoc V, Dey B, Berger EA.

Retrovirology. 2010 Feb 16;7:11. doi: 10.1186/1742-4690-7-11.

16.

Specific sequences commonly found in the V3 domain of HIV-1 subtype C isolates affect the overall conformation of native Env and induce a neutralization-resistant phenotype independent of V1/V2 masking.

Salomon A, Krachmarov C, Lai Z, Honnen W, Zingman BS, Sarlo J, Gorny MK, Zolla-Pazner S, Robinson JE, Pinter A.

Virology. 2014 Jan 5;448:363-74. doi: 10.1016/j.virol.2013.10.007. Epub 2013 Nov 12.

17.

Neutralization of HIV-1 by F105, a human monoclonal antibody to the CD4 binding site of gp120.

Posner MR, Cavacini LA, Emes CL, Power J, Byrn R.

J Acquir Immune Defic Syndr. 1993 Jan;6(1):7-14.

PMID:
8417177
18.

Characterizing anti-HIV monoclonal antibodies and immune sera by defining the mechanism of neutralization.

Crooks ET, Moore PL, Richman D, Robinson J, Crooks JA, Franti M, Schülke N, Binley JM.

Hum Antibodies. 2005;14(3-4):101-13.

19.

Antigenic and 3D structural characterization of soluble X4 and hybrid X4-R5 HIV-1 Env trimers.

Arnold P, Himmels P, Weiß S, Decker TM, Markl J, Gatterdam V, Tampé R, Bartholomäus P, Dietrich U, Dürr R.

Retrovirology. 2014 May 30;11:42. doi: 10.1186/1742-4690-11-42.

Supplemental Content

Support Center